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Abstract
Preterm infants have an impaired gut barrier function. We aimed to determine the effects of enteral supplementation of a prebiotic
mixture consisting of neutral oligosaccharides (short-chain galacto-oligosaccharides (SCGOS)/long-chain fructo-oligosaccharides
(LCFOS)) and acidic oligosaccharides (AOS) on intestinal permeability of preterm infants as measured by the sugar absorption test in the
first week of life. Furthermore, we determined host- and treatment-related factors associated with intestinal permeability. In a randomised
controlled trial, preterm infants with a gestational age ,32 weeks and/or birth weight (BW) ,1500 g received enteral supplementation
of SCGOS/LCFOS/AOS or placebo (maltodextrin) between days 3 and 30 of life. Intestinal permeability, reflected by the urinary lactu-
lose/mannitol (L/M) ratio after oral ingestion of lactulose and mannitol, was assessed at three time points: before the start of the study
(t ¼ 0), at day 4 (t ¼ 1) and at day 7 (t ¼ 2) of life. Data were analysed by generalised estimating equations. In total, 113 infants were
included. Baseline patient and nutritional characteristics were not different between the SCGOS/LCFOS/AOS (n 55) and the placebo
groups (n 58). SCGOS/LCFOS/AOS had no effect on the L/M ratio between t ¼ 0 and t ¼ 2. In both the groups, the L/M ratio decreased
from t ¼ 0 to t ¼ 2 (P,0·001). Low BW increased the L/M ratio (P¼0·002). Exclusive breast milk feeding and mixed breast milk/formula
feeding during the first week of life decreased the L/M ratio (P,0·001 and P,0·05, respectively). In conclusion, enteral supplementation of
a prebiotic mixture does not enhance the postnatal decrease in intestinal permeability in preterm infants in the first week of life.
Key words: Preterm infants: Intestinal permeability: Prebiotics
Directly after birth, preterm infants have an impaired gut
barrier function, reflected by an increased intestinal
permeability(1,2). Due to this increased intestinal per-
meability, delayed intestinal colonisation and immaturity
of the host immune defence system, potentially pathogenic
bacteria may translocate from the intestinal lumen and
cause systemic infections(3–5). Early enteral feeding is asso-
ciated with decreased intestinal permeability(6). In a recent
study, intestinal permeability was decreased in preterm
infants who received breast milk feeding v. preterm infants
who received formula feeding(7). These beneficial effects
of breast milk may partially be attributed to the ‘bifido-
genic’ effect of human milk. Increasing the number of ‘bifi-
dogenic’ bacteria may improve gut barrier function and
prevent systemic infections from translocation of gut
bacteria(8,9). Non-human milk oligosaccharides such as
short-chain galacto-oligosaccharides (SCGOS) and long-
chain fructo-oligosaccharides (LCFOS) have been deve-
loped(10). Non-human milk acidic oligosaccharides (AOS)
can be derived from pectin. In studies with non-human
milk oligosaccharides, enteral supplementation of neutral
oligosaccharides stimulates the growth of bifidobacteria
and lactobacilli, resulting in increased SCFA production(10).
In an in vitro model, SCFA were able to stimulate mucin-2
production and improve gut barrier function(11). In an
experimental animal study, a diet containing a prebiotic
mixture of inulin and oligofructose had a trophic effect on
colonic mucosal architecture(12). In addition, translocation
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of Salmonella typhimurium after oral inoculation was
partly decreased by the prebiotic diet(13), suggesting a
beneficial effect on gut barrier function.
In the initial study, we found a trend towards a decreased
incidence of serious endogenous infections after enteral
supplementation of a prebiotic mixture consisting of
neutral oligosaccharides (SCGOS/LCFOS) and AOS, if
given in sufficient amounts(14). We hypothesised that the
lower endogenous infection rate in preterm infants receiv-
ing SCGOS/LCFOS/AOS may originate from an improved
gut barrier function.
Until now, studies into the effect of prebiotics on intesti-
nal permeability in adults and newborn infants showed
controversial results(9,15–19). In preterm infants, intestinal
permeability was found to decrease spontaneously in
the first week of life(1,2,19,20). We hypothesise that enteral
supplementation of a prebiotic mixture consisting of
neutral oligosaccharides (SCGOS/LCFOS) and AOS may
improve gut barrier function, especially in the first week
of life, as reflected by decreased intestinal permeability.
Therefore, the aim of the present study was to determine
the effect of enteral supplementation of SCGOS/LCFOS/
AOS on intestinal permeability as measured with the
sugar absorption test (SAT) in the first week of life in
preterm infants. Furthermore, we determined host- and
treatment-related factors associated with intestinal per-
meability in these preterm infants.
Experimental methods
Subjects
Infants with a gestational age (GA) ,32 weeks and/or
birth weight (BW) ,1500 g admitted to the level III
neonatal intensive care unit (NICU) of the VU University
Medical Center, Amsterdam were eligible for participation
in the study. Exclusion criteria were small-for-GA infants
with a GA .34 weeks, major congenital or chromosomal
anomalies, death ,48 h after birth and transfer to another
hospital ,48 h after birth. The present study was con-
ducted according to the guidelines laid down in the
Declaration of Helsinki, and all procedures involving
human patients were approved by the medical ethical
review board of our hospital. Written informed consent
was obtained from all the parents.
Randomisation, blinding and treatment
After assignment to one of three BW groups (#799,
800–1199 and $1200 g), infants were randomly allocated
,48 h after birth to receive either an enteral supplemen-
tation of a prebiotic mixture of 80 % SCGOS/LCFOS and 20 %
AOS or a placebo mixture of maltodextrin. An independent
researcher used a computer-generated randomisation table
(provided by Danone Research, Friedrichsdorf, Germany)
to assign infants to treatment with SCGOS/LC FOS/AOS or
placebo. Investigators, parents, medical and nursing staff
were unaware of treatment allocation. The randomisation
code was broken after complete data analysis had been
performed.
SCGOS/LCFOS/AOS and the placebo (maltodextrin) were
prepared and packed sterile (Danone Research). The two
powders were indistinguishable by appearance, colour
and smell. During the study period, SCGOS/LCFOS/AOS
and placebo were monitored for stability and possible
microbiological contamination.
The supplementation of SCGOS/LCFOS/AOS or placebo
was administered in increasing doses between days 3
and 30 of life to a maximum of 1·5 g/kg per d to breast
milk or preterm formula (Nenatal Startw). Due to osmolar-
ity reasons, each infant had an individual feeding scheme
depending on BW and daily amount of feeding. If
an infant received #100 ml/kg per d enteral feeding, 1 g
SCGOS/LCFOS/AOS or placebo was added per 60 ml enteral
feeding. If an infant received .100 ml/kg per d, 1 g
SCGOS/LCFOS/AOS or placebo was added per 100 ml
enteral feeding. Two members of the nursing staff added
the daily supplementation to breast milk or to preterm
formula according to the parents’ choice. Per 100 ml, the
preterm formula provided 350 kJ (80 kcal), 2·4 g protein
(casein-to-whey protein ratio 40:60), 4·4 g fat and 7·8 g
carbohydrate. The preterm formula did not contain oligosac-
charides. When infants were transferred to another hospital
before the end of the study, the protocol was continued
under supervision of the principal investigator (E. A. M. W.).
Nutritional support
Protocol guidelines for the introduction of parenteral and
enteral nutrition followed current practice at our NICU.
Nutritional support was administered as previously
described(21), except for minimal enteral feeding which
was defined as 12–24 ml/kg per d. Enteral nutrition was
advanced either from day 2 or from day 4 in case of a BW
,10th percentile, GA,26 weeks, Apgar score,6 at 5 min,
umbilical artery pH ,7·10 or base deficit .10 mmol/l.
For each infant in the study, a feeding schedule was
proposed based on BW and the guidelines as mentioned
previously. After discharge, all the infants received
breast milk or preterm formula (Nenatal Startw without
oligosaccharides) until term, and a post-discharge formula
(Nenatal 1w without oligosaccharides) until the corrected
age of 6 months. The medical staff of our NICU and the
responsible paediatricians in the regional hospitals had
final responsibility for the administration of parenteral nutri-
tion and advancement of enteral nutrition. Further details
on the initial study have previously been published(14,22).
Intestinal permeability
Intestinal permeability was measured by SAT, as previously
described(2), at three time points: before the start of the
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study (t ¼ 0), at day 4 (t ¼ 1), and at day 7 (t ¼ 2) after
birth. In the SAT, urine was collected for 6 h after instilla-
tion of 2 ml/kg of the test solution (100 mg mannitol and
250 lactulose/5 ml sterile water) by nasogastric tube. After
collection, 0·1 ml chlorhexidine digluconate (20 %) was
added to the urine as a preservative, and samples were
stored at 2208C until analysis. Lactulose and mannitol
were measured by GC, and the lactulose/mannitol (L/M)
ratio was calculated.
Nutrition and clinical characteristics of the infants at the
time of SAT were assessed, including administration of type
of feeding in the week preceding the SAT, parenteral nutri-
tion, achievement of full enteral feeding and presence of
serious infection(s). A serious infection was defined as
sepsis, meningitis, pyelonephritis, pneumonia or arthritis
as diagnosed by a combination of clinical signs and a posi-
tive culture(23) within 48 h preceding the SAT.
Statistical analysis
The sample size of 113 infants was based on the sample
size calculation for the primary outcome of the main trial
(serious infectious morbidity). Normally distributed and
non-parametric data are presented as mean (SD) and
medians (ranges), respectively. Perinatal and nutritional
characteristics were analysed by Student’s t test, Mann–
Whitney U test, x 2 test or Fisher’s exact test for continuous
normally distributed, non-parametric continuous and
dichotomous data, respectively.
As the parameters of intestinal permeability had a skewed
distribution, a natural logarithmic transformation was per-
formed before analysis. In the primary analysis, generalised
estimating equations for longitudinal analysis were used to
compare changes in lactulose, mannitol and L/M ratio over
time between the groups(24). This method takes into account
the dependency of the observations within a patient and
the fact that samples may not be available at each time
point. Furthermore, the effect of host- and treatment-
related factors (chorioamnionitis, administration of ante-
natal corticosteroids, mode of delivery, GA, BW, Apgar
score at 5 min, administration of antibiotics postpartum,
serious infectious morbidity, necrotising enterocolitis(25),
time to full enteral feeding (.120 ml/kg per d), age at
finishing parenteral nutrition and type of feeding during
the first week of life on intestinal permeability) was deter-
mined by generalised estimating equation analysis. All the
statistical analysis was performed on an intention-to-treat
basis. For all the statistical analyses, a two-sided P value
,0·05 was considered significant. SPSS 15.0 (SPSS, Inc.,
Chicago, IL, USA) was used for data analysis.
Results
Between May 2007 and November 2008, 113 of 208 eligible
preterm infants entered the study. Reasons for not partici-
pating in the study were no informed consent (n 45),
participation in another trial (n 7), transfer to a regional
hospital within 48 h (n 12), death within 48 h (n 5) and
severe congenital malformations (n 12). After randomis-
ation, one infant in the placebo group was excluded,
because of strong suspicion of a syndrome. Baseline
patient and nutritional characteristics were not different in
SCGOS/LCFOS/AOS (n 55) and placebo groups (n 58)
(14)
(Table 1). SAT was performed at 36 (SD 15) h after
birth (t ¼ 0), at postnatal day 4·5 (SD 0·7) (t ¼ 1) and at
postnatal day 7·1 (SD 0·5) (t ¼ 2). At t ¼ 0, 17/55 (30·9 %)
and 10/58 (17·1 %), at t ¼ 1, 20/55 (36·4 %) and 11/58
(19·0 %), and at t ¼ 2, 15/55 (27·3 %) and 15/58 (25·9 %)
of the SAT data were missing in the SCGOS/LCFOS/AOS
and placebo groups, respectively. Missing SAT data could
mainly be attributed to insufficient urine collections. In
both groups, the L/M ratio showed a decrease from t ¼ 0
(0·21 (0·03–2·16) v. 0·34 (0·06–1·86) in SCGOS/LCFOS/
AOS-supplemented and placebo groups, respectively, to
t ¼ 2 (0·06 (0·00–0·68) v. 0·09 (0·00–2·68)) in SCGOS/
LCFOS/AOS-supplemented and placebo groups, respect-
ively (effect 0·34 (95 % CI 0·22, 0·51; P,0·001) (Fig. 1(a)).
Analysis by generalised estimating equations showed no
effect of enteral supplementation of SCGOS/LCFOS/AOS
on the decrease in L/M ratio. Lactulose and mannitol con-
centrations were not different in the SCGOS/LCFOS/AOS-
supplemented and placebo groups (Fig. 1(b) and (c)).
As there were no significant differences between the SC-
GOS/LCFOS/AOS-supplemented and placebo groups, both
the groups were analysed together to determine the influ-
ence of different host- and treatment-related factors on
intestinal permeability (Table 2). Increased BW was related
to decreased intestinal permeability (effect 0·54 (95 % CI
0·36, 0·81; P¼0·002)). Both exclusively breast milk feeding
and mixed breast milk/formula feeding in the first week of
life decreased the L/M ratio compared with exclusively for-
mula feeding (effect 0·49 (95 % CI 0·34, 0·73; P,0·001) and
0·53 (95 % CI 0·30, 0·93; P,0·05), respectively). At t ¼ 2,
22/113 (20 %) of the infants had a serious infection. SAT
was performed in 16/22 (73 %) of the infants with a serious
infection. The median L/M ratio was not different in
infants with a serious infection and infants without a
serious infection. In total, sixteen infants developed necro-
tising enterocolitis. The median age at which infants deve
loped necrotising enterocolitis was 21 d (6–60). The
median L/M ratio was not different in infants who later
developed necrotising enterocolitis compared to infants
who did not develop necrotising enterocolitis (Table 2).
Discussion
In preterm infants, we found that enteral supplementation
of a prebiotic mixture consisting of neutral oligosacchar-
ides (SCGOS/LCFOS) and acidic (AOS) oligosaccharides
does not decrease intestinal permeability in the first week
of life, as measured by the SAT. The present results are
in line with a study in healthy newborns(18). Also, in
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adult burn patients, prebiotic supplementation did not
decrease intestinal permeability(15).
The lack of effect of prebiotics on intestinal permeability
may be explained by high doses of antibiotics used in
patients, including preterm infants, admitted at a intensive
care unit, which interferes with the growth of bifidobac-
teria and lactobacilli(15). In two recent studies in preterm
infants, we found that antibiotics severely delayed the
intestinal colonisation(26,27). Delayed intestinal colonisation
decreases the production of SCFA which in turn impairs gut
barrier function(10,11). In the present study, 75 % of all
infants received antibiotics immediately after birth. Further-
more, the prebiotic supplementation dose in the present
study may have been insufficient to reach an (maximal)
effect on intestinal permeability. This is in accordance
with the trend towards a lower incidence of endogenous
infections if preterm infants received prebiotics in a suffi-
cient amount and numbers of days(14). In the literature,
few data are available about the optimal type, combination
and amount of prebiotic supplementation(28). Olguin
et al.(15) used one type of prebiotics (oligofructose), and
Colome´ et al.(18) did not state which type and amount
of prebiotics were given. Furthermore, probiotics and,
especially, the combination of pre- and probiotics could
be used, because a synergistic or additional effect may
exist(28). Stratiki et al.(19) found that administration of a pro-
biotic (Bifidobacterium lactis)-supplemented formula
decreased intestinal permeability of preterm infants at
day 30. In adult trauma patients, synbiotic, but not pre-
biotic (fermentable fibres), supplementation decreased
intestinal permeability(16).
The timing of the prebiotic supplementation may also
explain the varying effects on intestinal permeability.
The mean age of infants in the study of Colome´ et al.(18)
was 74·4 (SD 30·3) d which could explain the lack of
effect on intestinal permeability of the prebiotic supple-
mentation, as previous studies show that intestinal
permeability decreases rapidly in the first week of
life(1,2). Stratiki et al.(19) found that probiotics decreased
intestinal permeability at day 30 of life, but not at day 7.
This finding suggests that supplementation of prebiotics,
probiotics or synbiotics may affect intestinal permeability,
if given for a sufficient number of days.
Postnatal factors may play an important role in the rapid
adaptation of the small intestine to the extrauterine circum-
stances(20). In the present study, we found that both exclu-
sively breast milk feeding and mixed breast milk/formula
feeding during the first week of life decreased intestinal
permeability at day 7. This is in line with a recent study
done by Taylor et al.(7) who found a decreased intestinal
permeability in preterm breast-fed infants during the first
30 d of life. A decreased intestinal permeability after
breast milk feeding was also found in term infants(6,29).
This positive effect of breast milk feeding may be attributed
to the ‘bifidogenic’ effect of breast milk and supports
the hypothesis that the intestinal microbiota plays an
important role in gut barrier function. The intestinal micro-
biota communicates with the underlying epithelium, which
may lead to metabolic and immunologic reactions by
the epithelial cells and its underlying lymphoid cells.
This process is called bacterial–epithelial ‘crosstalk’(30,31).
Preterm infants have an inadequate maturation of the
Table 1. Baseline and nutritional characteristics*
(Percentage values, standard deviations and ranges)
Prebiotic mixture (n 55) Placebo (n 58)
Variable† Infants (%) SD/range Infants (%) SD/range
Baseline characteristics
Chorioamnionitis 20 22
PE, E or HELLP 31 31
Placental insufficiency 7 5
Antenatal antibiotics 20 28
Antenatal corticosteroids (%) 56 56
Multiple birth 16 22
Vaginal delivery (%) 56 55
Gestational age (weeks) 29·9 1·9 29·3 2·1
Birth wt (kg) 1·3 0·4 1·2 0·3
Birth wt ,10th percentile‡ 22 14
Sex (% male) 56 62
Apgar score at 5 min ,6 16 9
Antibiotics postpartum 75 76
Nutritional characteristics
Age at the start of study supplementation (d) 2·1 1·5–5·3 2·1 1·5–3·3
Time to full supplementation dose (d) 11 4–28 11 5–27
Mean supplementation dose during the study period (g/kg per d) 1·30 0·1–1·6 1·27 0·2–1·8
Age at introduction of enteral nutrition (d) 2·8 0·6–27·5 2·5 0·3–18·0
Exclusive breast milk during the 30 d study period (%) 69 57
PE, pre-eclampsia; E, eclampsia; HELLP, syndrome of haemolysis, elevated liver enzymes and low platelets.
* Baseline and nutritional characteristics were not statistically different (P,0·05) between the prebiotic mixture and placebo group.
† Student’s t test, Mann–Whitney U test and x 2 test or Fisher’s exact test are used to analyse continuous normally distributed, non-parametric continuous data, respectively.
‡ According to Usher & McLean(39).
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host immune defence system, and due to an inappropriate
bacterial–epithelial ‘crosstalk’(31), they have an increased
risk to develop serious infections. However, the decreased
incidence of endogenous infections(14) could not be
explained by improved gut barrier function, as reflected
by intestinal permeability.
Besides a high risk for serious infectious morbidity, pre-
term infants are at high risk for developing necrotising
enterocolitis. The pathogenesis of necrotising enterocolitis
is not completely understood, but it has been proposed
that impaired gut barrier function plays a crucial role(32).
In a rat gavage model, Zani et al.(33) found that rats with
experimentally induced necrotising enterocolitis have
increased intestinal permeability and develop systemic
symptoms such as cardiac damage and renal failure. This
suggests bacterial translocation and transfer of endotoxin
and other inflammatory mediators causing multi-organ
failure(33). In the present study, we did not find an
increased intestinal permeability in infants who developed
necrotising enterocolitis. However, in most cases, the SAT
was performed before the infants developed necrotising
enterocolitis.
Some remarks may be formulated with regard to the
methodology of the present study. First, we only measured
intestinal permeability in the first week of life. Study
supplementation started at a median postnatal age of 2 d.
At postnatal day 7, 86/113 (76 %) of the infants had not
yet reached a supplementation dose of 1·5 g/kg per d.
The mean supplementation dose during the first week of
life was 0·73 (SD 0·43) g/kg per d. Therefore, infants may
not have received a sufficient dose of SCGOS/LCFOS/AOS
supplementation to reach a significant effect at postnatal
day 4 or 7. However, in an additional analysis, we did
not find a relationship between supplementation dose
during the first week of life and intestinal permeability.
Furthermore, in a previous study, in the first week of life,
a significant decrease of the intestinal permeability was
found, and during the next 3 weeks, the intestinal per-
meability remained stable(21). Therefore, we hypothesised
Table 2. Factors influencing intestinal permeability (lactulose/mannitol
(L/M) ratio) in preterm infants
(Effects and 95 % confidence intervals)
Effect† 95 % CI
Chorioamnionitis 0·93 0·65, 1·32
Antenatal corticosteroids 1·01 0·75, 1·37
Vaginal delivery 0·96 0·72, 1·31
Gestational age (weeks) 0·95 0·88, 1·02
Birth wt (kg) 0·54** 0·36, 0·81
Apgar score at 5 min ,6 0·91 0·59, 1·40
Antibiotics postpartum 1·02 0·46, 1·39
Infection ,48 h before sample
at day 7‡
0·87 0·53, 1·42
Necrotising enterocolitis 1·22 0·76, 1·97
Time to full enteral feeding 1·01 0·98, 1·03
Age at finishing parenteral nutrition 1·00 0·98, 1·04
Exclusive breast milk in the
firstweek of life§
0·49*** 0·34, 0·73
Mixed breast milk and formula feeding
in the first week of life§
0·53* 0·30, 0·93
The factor significantly influenced intestinal permeability: *P,0·05, **P,0·01,
***P,0·001.
† Data indicate the effect of a factor on the L/M ratio at all time points (generalised
estimated equations). The effect can be interpreted as follows: in case of
chorioamnionitis, the L/M ratio is 0·93 (95 % CI) times as high as without
chorioamnionitis.
‡ Sepsis, meningitis, pyelonephritis, pneumonia or arthritis as diagnosed by a
combination of clinical signs and a positive culture ,48 h preceding sugar
absorption test.




































































Fig. 1. Results of sugar absorption tests. Results are expressed as median.
Time points: before the start of the study (t ¼ 0), at day 4 (t ¼ 1) and at day
7 (t ¼ 2) after birth. (a) Urinary lactulose/mannitol (L/M) ratio. (b) Urinary
lactulose concentrations. (c) Urinary mannitol concentrations. B, Prebiotic
mixture; A, placebo. There were no significant differences between both the
groups (generalised estimated equations).
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that the maximum effect of prebiotic supplementation on
intestinal permeability would be in the first week of life.
In the present study, intestinal permeability decreased in
both the groups from day 1 to day 7. This is in line with
previous studies(1,2,19,20). Secondly, breast milk itself
contains neutral and AOS and, as shown in the present
study, breast milk feeding has a positive effect on intestinal
permeability. Therefore, the effect of enteral supplemen-
tation of SCGOS/LCFOS/AOS may be less pronounced in
preterm infants who exclusively received breast milk. As
breast milk is strongly promoted at our NICU, most infants
received breast milk feeding (.60 %), and relatively few
received exclusively formula feeding (20 %).
There were no serious adverse events reported after
prebiotic supplementation in two recent reviews on pre-
biotic supplementation, including preterm infants(34,35).
However, Barrat et al.(36) found an increased bacterial
translocation in the intestine of immature rats (‘pup in the
cup model’) fed a milk formula containing GOS and inulin,
without an effect on intestinal permeability. However,
intestinal permeability was measured in vitro with Ussing
chambers(36). The mechanisms underlying this increased
bacterial translocation are unclear and should be investi-
gated further. Bacterial translocation may originate from a
combination of increased intestinal permeability, delayed
intestinal colonisation and immaturity of the host immune
defence(3,5). It has been speculated that the increased
bacterial translocation may not necessarily be harmful,
but may be involved in the postnatal maturation of the
immune system(37,38). Urao et al.(37) and Gebbers &
Laissue(38) speculate that bacterial translocation may be
instrumental for tolerance induction against the endo-
genous microbiota and for the stimulation and normal
development of the gut-associated lymphoid tissue.
In conclusion, the present study in preterm infants
shows that enteral supplementation of a prebiotic mixture
consisting of neutral (SCGOS/LCFOS) and acidic (AOS)
oligosaccharides does not enhance the decrease in intesti-
nal permeability in the first week of life, as measured by
the SAT. Breast milk feeding during the first week of life
decreased the L/M ratio. The trend towards a lower inci-
dence of endogenous infection rate in preterm infants
receiving SCGOS/LCFOS/AOS cannot be explained by
improved gut barrier function, as reflected by intestinal
permeability in the first week of life. A beneficial effect
of SCGOS/LCFOS/AOS may involve other aspects of gut bar-
rier function; for example, modulation of the intestinal
microbiota and the intestinal inflammatory response.
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